Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

April 2016

Impact:

NHS Healthcall – An NHS collaboration driving improved care and technology innovation across the North East of England – produce patient information sheets citing 2012 Lancet review on self-monitoring.

May 2016

Impact:

Roche launches the CoaguChek® INRange system in countries accepting the CE Mark. Cite 2006 and 2012 systematic reviews on self-monitoring.

Roche also makes these related statements:

  • “CoaguChek meters have been offered in the U.S. for more than 20 years and there are more than one million CoaguChek XS devices in use around the world."
  • "Over 250,000 CoaguChek XS PT test strips are used globally per day."
  • "Nine of the top 10 U.S. integrated health networks (IHNs) choose CoaguChek technology."

July 2016

Underpinning research published:

Heneghan CJ, Garcia‐Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, Alonso‐Coello P, Fitzmaurice D, Mahtani KR, Onakpoya IJ. 
Self‐monitoring and self‐management of oral anticoagulation.
Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.: CD003839. DOI: 10.1002/14651858.CD003839.pub3

The above review is press released. Lead author statement: “There are more than 1.2 million people in the UK on warfarin therapy, of whom fewer than 2 per cent self-monitor their INR levels despite mounting evidence that self-monitoring alone can cut the risk of death by nearly two fifths and more than half the risk of strokes.”

September 2016

BMJ Editorial:

Novel oral anticoagulants for atrial fibrillation 
Mahtani, K.R. and Heneghan, C.
BMJ (2016): i5187.